Home » Topics » Regulatory » EMA

EMA
RSS

Isis Pharmaceuticals begins phase I/IIa trial of ISIS-HTTRx in Huntington's disease

July 22, 2015

Swedish Orphan Biovitrum exercises Alprolix opt-in right

July 16, 2015

Prima Biomed receives positive scientific advice from the EMA for IMP-321

July 8, 2015

Intercept files for approval of obeticholic acid for primary biliary cirrhosis in U.S. and E.U.

June 30, 2015

EMA committee recommends approval of Raxone for Leber's hereditary optic neuropathy

June 29, 2015

Farydak recommended by CHMP to treat multiple myeloma

June 29, 2015

CHMP adopts positive opinions for Strensiq and Kanuma

June 29, 2015

Humira recommended for approval for hidradenitis suppurativa in E.U.

June 29, 2015

MM-398 accepted for review in E.U., granted priority review by FDA

June 26, 2015

Alexion completes acquisition of Synageva BioPharma

June 26, 2015

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 30, 2026.
Emerging therapeutic strategies for Parkinson’s at ADPD 2026
BioWorld
Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...
Small-molecule TREM2 agonist advances to treat Alzheimer’s
BioWorld Science
Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...
With improved technologies, biomarkers, failed drugs may come into their own
BioWorld
At BioEurope Spring 2026, pharma representatives and investors shared their thoughts about current and future landscapes of different disease areas, and on how to...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 24, 2026